Infertility is frequently discussed, researched, and treated as a condition primarily affecting women. The tests, the medications, the procedures, the clinical attention — in most fertility practices, most of it falls on the female partner. The male partner provides a semen analysis. If the result falls within reference ranges, he is considered assessed. The investigation moves on.
This clinical pattern reflects a cultural assumption — that fertility is primarily a female responsibility — that is not supported by the clinical evidence. Male factor infertility contributes to approximately 40 to 50 percent of all infertile couples. In approximately 20 to 30 percent of cases, male factor is the primary or sole cause. And in a significant additional proportion, male factor is a contributing cause alongside female factors — a combination that will not be fully addressed if male investigation stops at a standard semen analysis.
The most important single thing this article communicates is that male infertility is real, common, frequently underdiagnosed, and in many cases effectively treatable — provided the investigation is thorough enough to identify the specific cause, and the treatment is matched to that cause rather than applied generically.
The Biology of Male Fertility
Male fertility depends on three fundamental requirements: adequate sperm production in the testes, successful maturation and transport of sperm through the reproductive tract, and the functional capacity of the ejaculated sperm to fertilize an egg.
The process of sperm production — spermatogenesis — takes place continuously in the seminiferous tubules of the testes. From a single spermatogonial stem cell, a sequence of cell divisions and maturation steps produces mature spermatozoa over approximately 72 days. The mature sperm then spend approximately twelve to twenty-one days in the epididymis — a coiled tube adjacent to each testis — where they undergo further maturation and acquire the motility and fertilizing capacity they will need.
At ejaculation, sperm from the epididymis are transported through the vas deferens to the ejaculatory ducts, where they mix with secretions from the seminal vesicles and prostate gland to form the semen. The total volume of semen is approximately 2 to 5 mL, of which the sperm themselves constitute less than 5 percent.
Any disruption to the hormonal signals that drive spermatogenesis, to the structural integrity of the testicular tissue that carries it out, to the ductal system that transports sperm, or to the functional capacity of the sperm themselves, can result in male infertility.
The Causes of Male Infertility: A Complete Overview
Male infertility has many causes — and identifying the specific cause matters clinically because different causes have different treatments, and treating the wrong cause is both ineffective and wasteful of the biological time the couple cannot recover.
Pretesticular Causes — Hormonal
Pretesticular causes are those that impair spermatogenesis by disrupting the hormonal signaling that drives it, rather than by directly damaging the testicular tissue.
Hypogonadotropic hypogonadism is the most important pretesticular cause. In this condition, the pituitary gland fails to produce adequate levels of FSH and LH — the gonadotropins that stimulate the testes to produce testosterone and sperm. Without adequate gonadotropin stimulation, spermatogenesis does not occur or is severely impaired. Causes include pituitary tumors, Kallmann syndrome (a genetic condition combining hypogonadism with absent sense of smell), and in some cases the use of anabolic steroids or testosterone replacement therapy, which suppress endogenous gonadotropin production.
Hypogonadotropic hypogonadism is one of the most treatable causes of severe male infertility — gonadotropin injections (FSH and hCG) administered for several months can stimulate spermatogenesis in previously azoospermic men and produce sperm adequate for natural conception or IVF.
Hyperprolactinemia — elevated prolactin — suppresses gonadotropin release and can cause secondary hypogonadism and impaired spermatogenesis. The cause is typically a benign pituitary adenoma (prolactinoma), and treatment with dopamine agonists (cabergoline or bromocriptine) normalizes prolactin, restores gonadotropin secretion, and improves sperm production.
Thyroid dysfunction affects the hormonal environment of spermatogenesis and can impair sperm production and quality.
Testicular Causes — Primary Spermatogenic Failure
Testicular causes are those that directly impair the sperm-producing capacity of the testicular tissue.
Varicocele — the most common correctable cause of male infertility. A varicocele is an abnormal dilation of the veins within the scrotum — analogous to varicose veins in the legs — that creates a local environment of elevated temperature, hypoxia, and oxidative stress within the testes. This environment directly impairs spermatogenesis and is one of the most important causes of elevated sperm DNA fragmentation. Varicocele is found in approximately 15 percent of all men, in approximately 35 percent of men with primary infertility, and in approximately 80 percent of men with secondary infertility after previous natural conception. Surgical or radiological treatment of varicocele improves sperm parameters and reduces DNA fragmentation in the majority of affected men.
Cryptorchidism — undescended testes — occurs when one or both testes fail to descend into the scrotum during fetal development. The elevated temperature of the abdominal or inguinal location impairs spermatogenesis, and even after surgical correction (orchidopexy) in childhood, impaired spermatogenic function may persist. Bilateral cryptorchidism is associated with higher rates of azoospermia and severe oligospermia in adult life.
Klinefelter syndrome — the most common genetic cause of male infertility — is a condition in which a man carries an extra X chromosome (47,XXY karyotype). The extra X chromosome causes testicular dysgenesis, elevated FSH, and typically severe oligospermia or azoospermia. As described in our earlier article on male infertility success stories, micro-TESE can retrieve sperm from a proportion of Klinefelter syndrome patients, making biological fatherhood possible in some cases.
Y chromosome microdeletions — deletions in specific regions of the Y chromosome (AZFa, AZFb, AZFc) that carry genes essential for spermatogenesis — are found in approximately 10 to 15 percent of men with non-obstructive azoospermia or severe oligospermia. AZFc deletions are associated with variable residual spermatogenesis and are the most amenable to sperm retrieval attempts. AZFa and AZFb deletions are associated with complete spermatogenic failure and a very low probability of finding sperm even with micro-TESE.
Previous mumps orchitis — viral infection of the testes — can cause permanent damage to seminiferous tubule function if it occurs after puberty.
Previous chemotherapy or radiotherapy — cytotoxic treatments for cancer — can permanently damage spermatogenic tissue. Fertility preservation (sperm banking or, in prepubertal boys, testicular tissue cryopreservation) before cancer treatment is the most effective strategy for preserving reproductive potential.
Idiopathic non-obstructive azoospermia or oligospermia — in which no specific cause is identified despite thorough investigation — accounts for a significant proportion of severe male infertility cases.
Post-Testicular Causes — Obstructive
Post-testicular causes are those that impair the transport of sperm from the testes to the ejaculate, despite normal or near-normal spermatogenesis.
Vasectomy — deliberate surgical occlusion of the vas deferens — is the most common cause of obstructive azoospermia. Men who have had a vasectomy and later wish to have children can consider vasectomy reversal surgery (vasectomy reversal) or sperm retrieval through PESA or TESA for use in IVF/ICSI.
Congenital bilateral absence of the vas deferens (CBAVD) — the vas deferens is absent from birth, typically in association with cystic fibrosis gene mutations. Men with CBAVD have normal spermatogenesis but cannot ejaculate sperm — sperm must be retrieved surgically through PESA or TESA for IVF/ICSI.
Epididymal obstruction — blockage of the epididymis, typically from previous infection or inflammation (epididymo-orchitis) or from previous scrotal surgery — prevents sperm from reaching the ejaculatory system despite normal testicular production.
Ejaculatory duct obstruction — blockage of the ejaculatory ducts by cysts or inflammatory scarring — prevents sperm from being expelled during ejaculation.
Sperm Functional Causes — Beyond Standard Parameters
Sperm DNA fragmentation — as discussed extensively throughout this content library — is a cause of male factor infertility that is invisible to standard semen analysis and requires specific testing. High DNA fragmentation impairs embryo development, reduces implantation rates, and increases miscarriage rates in ways that are not captured by count, motility, or morphology measurements.
Antisperm antibodies — produced by the immune system against the man's own sperm — can impair sperm motility, agglutination, and the ability of sperm to penetrate cervical mucus and the zona pellucida of the egg. They can develop after vasectomy reversal or after injury to the blood-testis barrier.
Tests for Male Infertility: What the Investigation Should Include
A complete male infertility investigation at Metro IVF is significantly more thorough than the standard semen analysis — because the standard semen analysis is the beginning of the investigation, not its entirety.
Complete semen analysis with strict morphology. A fresh sample, collected after two to five days abstinence, assessed using strict Kruger criteria for morphology. As explained in our plain language guide to semen analysis, this provides count, motility, morphology, volume, pH, viscosity, and leukocyte assessment.
Sperm DNA fragmentation testing. Essential in any couple with unexplained infertility, repeated IVF failure, recurrent miscarriage, or any pattern suggesting sperm quality issues below the level of standard analysis. Performed through DFI measurement — TUNEL, SCSA, or Comet methodology.
Hormonal assessment. FSH, LH, testosterone, and prolactin — providing information about the hypothalamic-pituitary-testicular axis. Elevated FSH with low testosterone suggests primary testicular failure. Low FSH with low testosterone suggests hypogonadotropic hypogonadism. Elevated prolactin suggests a pituitary cause requiring specific investigation.
Scrotal Doppler ultrasound. Direct assessment of the testes and scrotal contents — testicular volume, echogenicity, epididymal morphology, and the presence and grade of varicocele. More sensitive than clinical examination for detecting varicocele.
Genetic testing. Karyotype and Y chromosome microdeletion analysis — recommended in any man with non-obstructive azoospermia or severe oligospermia (below 5 million/mL), or where clinical features suggest Klinefelter syndrome. CFTR gene testing (for cystic fibrosis mutations) is recommended in men with CBAVD.
Testicular biopsy / surgical sperm retrieval assessment. In azoospermic men, the distinction between obstructive and non-obstructive azoospermia — determined by the combination of clinical history, physical examination, hormonal profile, and ultrasound findings — determines the likelihood of successful surgical sperm retrieval and the appropriate retrieval technique.
Treatment Options for Male Infertility
Treatment is matched to cause. The following are the most important treatments available, aligned with the conditions they address.
Varicocele treatment — surgical ligation or radiological embolization — improves sperm parameters and reduces DNA fragmentation in men with clinical varicocele and associated sperm quality impairment. Improvement is typically seen within three to six months after treatment, corresponding to one to two spermatogenesis cycles.
Gonadotropin therapy — FSH and hCG injections administered over several months — induces spermatogenesis in men with hypogonadotropic hypogonadism, including those who were previously azoospermic.
Medical treatment of hyperprolactinemia — dopamine agonist therapy normalizes prolactin and restores gonadotropin secretion, improving sperm production in men with prolactinoma-associated infertility.
Antioxidant therapy — CoQ10, vitamin C, vitamin E, zinc, selenium, and other antioxidants — reduces oxidative stress and sperm DNA fragmentation in men with elevated DFI, particularly those with mild to moderate elevation or those with identifiable oxidative stress risk factors. Requires two to three months of treatment to affect DFI through a full spermatogenesis cycle.
Lifestyle modification — smoking cessation, alcohol reduction, weight management, heat avoidance, and occupational toxin reduction — reduces oxidative stress and improves sperm parameters in men with modifiable risk factors.
PESA (Percutaneous Epididymal Sperm Aspiration) — retrieval of sperm directly from the epididymis through a fine needle aspiration — for men with obstructive azoospermia. Retrieved sperm are used in IVF/ICSI.
TESA (Testicular Sperm Aspiration) — retrieval of sperm directly from the testicular tissue through needle aspiration — for men with obstructive azoospermia where PESA is unsuccessful, or for men with non-obstructive azoospermia where focal spermatogenesis may be present.
Micro-TESE (Microsurgical Testicular Sperm Extraction) — systematic examination of testicular tissue under an operating microscope to identify and retrieve sperm from focal areas of active spermatogenesis — for men with non-obstructive azoospermia in whom standard TESA does not yield sperm. Success rates of sperm retrieval in appropriately selected non-obstructive azoospermia cases range from 40 to 60 percent.
IVF with ICSI — in vitro fertilization with intracytoplasmic sperm injection — the cornerstone of treatment for most forms of severe male factor infertility. ICSI allows fertilization with a single sperm, bypassing the need for sperm to swim to and penetrate the egg independently, making pregnancy possible in cases of very severe oligospermia or with surgically retrieved sperm.
The Critical Importance of Treating Both Partners
Male infertility does not exist in isolation. It exists within the context of a couple's fertility — and addressing the male factor without simultaneously attending to the female partner's fertility assessment is an incomplete approach.
At Metro IVF, both partners are investigated with equal thoroughness from the beginning. The male investigation — including sperm DNA fragmentation testing as a routine component — runs in parallel with the female investigation. The treatment recommendations that follow address the complete picture of both partners' fertility, not just the factor that is most obviously abnormal.
This parallel, equally thorough approach is what distinguishes Metro IVF's practice from clinics that focus investigation primarily on the woman and address the male factor only when the semen analysis is obviously abnormal. It is also what produces better outcomes — because the full picture, including the male contribution, is the basis of the most accurate clinical decision-making.
Your Next Step
If male infertility is a concern — whether you have received an abnormal semen analysis result, been told your result is normal but your IVF cycles have failed, or suspect that the male investigation has not been thorough enough — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur provides the most complete male fertility assessment available in the region.
The investigation at Metro IVF is not limited to what a standard semen analysis provides. It is designed to find the cause — and finding the cause is the foundation of the treatment that actually works.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
Male infertility is half the picture. Make sure your half has been completely assessed. Book your consultation with Dr. Ashish Soni at Metro IVF today.